PRINCETON, N.J. / Nov 26, 2024 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in Citi’s 2024 Global Healthcare Conference.
Christopher Boerner, Ph.D., board chair and chief executive officer, will take part in a fireside chat on December 3, 2024. He will answer questions about the company beginning at 8:00 a.m. ET.
Investors and the general public are invited to listen to a live webcast of the session by visiting http://investor.bms.com. An archived edition of this session will be available following its conclusion.
About Bristol Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, X, YouTube, Facebook, and Instagram.
| Last Trade: | US$53.95 |
| Daily Change: | -0.26 -0.48 |
| Daily Volume: | 7,135,701 |
| Market Cap: | US$110.060B |
December 08, 2025 December 03, 2025 December 01, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
